Because there is no drug to regulate KLK5, our findings pave the way for future studies to investigate the potential use of triterpenoids as an anti-KLK5 drug and as a therapeutic drug against refractory skin diseases such as rosacea and atopic dermatitis. The gene discussed is KLK5; the disease is atopic eczema.